Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta

Roche Holding AG subsidiaries accused Shanghai Henlius Biotech Inc. and Organon & Co.'s proposed biosimilar version of Perjeta of infringing two dozen patents for the blockbuster breast-cancer drug.

Genentech Inc. and Hoffmann-La Roche Inc. seek to block the biosimilar’s launch until the patents expire, the companies said in a complaint filed Thursday in the US District Court for the District of New Jersey. The suit appears to be the first over a proposed biosimilar of Perjeta.

One of the asserted patents expired June 1, and the rest have expirations ranging through March 2039, according to the US Food and Drug ...